Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Outcome of Immune Checkpoint Inhibitors.

Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Outcome of Immune Checkpoint Inhibitors.

Publication date: Jul 15, 2019

A meta-analysis of 14 studies (16 cohorts) incorporating 1751 participants was performed to evaluate the correlation between baseline neutrophil-to-lymphocyte ratio (NLR) and outcome of immune checkpoint inhibitors (ICI). The pooled hazard ratio (HR) suggested elevated pretreatment NLR was associated with poor OS (HR: 2.61, 95% confidence intervals (CI): 1.77-3.86, p 

Xie, X., Liu, J., Yang, H., Chen, H., Zhou, S., Lin, H., Liao, Z., Ding, Y., Ling, L., and Wang, X. Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Outcome of Immune Checkpoint Inhibitors. 23378. 2019 Cancer Invest.

Concepts Keywords
Confidence Intervals Metastatic renal carcinoma
Correlation NSCLC
HR 2 Branches of biology
ICI Medicine
Lymphocyte Medical specialties
Meta Analysis Immune system
Neutrophil NLR
Melanoma
MRCC
Immune checkpoint
Checkpoint inhibitor

Semantics

Type Source Name
pathway BSID Non-small cell lung cancer
disease DOID non-small cell lung cancer
disease MESH non-small cell lung cancer
pathway BSID Renal cell carcinoma
disease DOID renal cell carcinoma
disease MESH renal cell carcinoma
pathway BSID Melanoma
disease DOID Melanoma
disease MESH Melanoma

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *